Company: INDP
Filing Date: 2025-06-23
Form Type: DEF 14A
Source: 0001641172-25-016071
Chunk: 14

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-23
Form: DEF 14A
Chunk 14
---
 the Purchase Agreement contains a provision
stating that in the event stockholder approval is required for the shares underlying the Notes and the Common Warrants, respectively,
the Company shall take all action necessary to hold a special meeting of its stockholders for the purpose of obtaining stockholder
approval.

Since the Conversion Price and the exercise price
of the Common Warrants and Placement Agent Warrants may be less than the Nasdaq Minimum Price, we are therefore seeking stockholder
approval for the Issuance Proposal.

We are not seeking the approval
of our stockholders to authorize our entry into the Private Placement, but rather to approve the conversion of the Notes and exercise
of the Common Warrants, Pre-funded Warrants and Placement Agent Warrants into shares of our common stock. As such, if the stockholders do not approve this proposal, any such Notes may not be converted into common
stock and any Common Warrant, Pre-funded Warrants and Placement Agent Warrants, if issued, will not convert into common stock.

If stockholders approve the Issuance Proposal,
the rights or privileges of our existing stockholders will not be affected, except that the economic and voting interests of each of
our existing stockholders will be diluted. Although the number of shares of our common stock that our existing stockholders own will
not decrease, the shares of our common stock owned by our existing stockholders will represent a smaller percentage of our total outstanding
shares of our common stock after any such issuance. Because the Conversion Price of the Notes and the exercise price of the Common Warrants
and Placement Agent Warrants are dependent upon the trading price of our common stock in the future, the exact magnitude of the dilutive
effect cannot be conclusively determined. However, the dilutive effect may be material to our current stockholders.

Vote Required

The proposal requires the affirmative vote of the holders of a majority
in voting power of the votes cast affirmatively or negatively. Abstentions will have the same legal effect as a negative vote. Broker
non-votes will have no effect on the proposal.

Recommendation of the Board of Directors

The Board of Directors unanimously recommends a vote FOR the Issuance Proposal.

<div align='center'>8</div>

PROPOSAL 2: RELATED PARTY PROPOSAL

We are seeking stockholder approval, for purposes
of complying with Nasdaq Listing Rule 5635(c), of the issuance of (i) shares of our common stock underlying Notes issued or issuable
in the ongoing Private Placement